• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Report: More than 430 medicines in development for chronic diseases in elderly

Report: More than 430 medicines in development for chronic diseases in elderly

June 19, 2014
CenterWatch Staff

America’s biopharmaceutical research companies are developing 435 innovative new medicines to target 15 leading chronic conditions affecting the Medicare population, according to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA).

These medicines in development—all either in clinical trials or under review by the FDA—are diverse in scope. They include:

  • 110 for diabetes, which affects 10.9 million Americans age 65 and older
  • 62 for rheumatoid arthritis and osteoarthritis, which affect 1.5 million and 27 million Americans respectively
  • 67 for Alzheimer’s disease, which could affect 15 million people in the U.S. by 2050 if no new medicines are found to prevent, delay or stop the progression of the disease
  • 61 for heart disease—heart failure, hypertension, ischemic heart disease and high cholesterol
  • 40 for chronic obstructive pulmonary disease (COPD), which affects approximately 13 million adults, with the highest prevalence rate in those over age 65.

With the aging population and life expectancy climbing, higher rates of chronic diseases remain a major challenge for our health care system. Tremendous advances in medical science, combined with the benefits of lifestyle changes, have allowed more individuals to continue living their lives with one or more chronic illnesses. Today nearly 92% of older adults have at least one chronic condition, and 77% have at least two, according to the National Council on Aging (NCOA).

“Treatment advances have led to significant progress against many chronic diseases, but challenges remain,” said John J. Castellani, PhRMA president and CEO. “The 435 medicines in the pipeline today offer incredible hope for aging patients and the sustainability of our health care system.”

According to NCOA, chronic diseases account for 75% of the money the U.S. nation spends on health care, with direct healthcare expenditures for chronic conditions in the U.S. totaling more than $262 billion in 2009. Among older Americans, 95% of healthcare costs are for chronic diseases, with the cost of providing healthcare for one person aged 65 or older being three to five times higher than the cost for someone younger than 65, according to data from the Centers for Disease Control and Prevention.

Chronic diseases pose their greatest risks as people age, with heart disease and cancer leading the pack, along with stroke, Alzheimer’s disease and diabetes. However, the ability to prevent, manage and treat chronic diseases has progressed dramatically in recent years, due in large part to the discovery and availability of new innovative medicines.

Upcoming Events

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • tablet

    Digital Intake Platforms Effective as Source of Trial Information, Survey Shows

  • Diversity-360x240.png

    Site Spotlight: EmVenio Research Takes to the Road to Promote Trial Diversity

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing